Zollinger-Ellison syndrome classification: Difference between revisions
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
*The following table illustrates the differences between Sporadic and MEN-1-associated ZES: <ref name="pmid24319020">{{cite journal |vauthors=Epelboym I, Mazeh H |title=Zollinger-Ellison syndrome: classical considerations and current controversies |journal=Oncologist |volume=19 |issue=1 |pages=44–50 |year=2014 |pmid=24319020 |pmc=3903066 |doi=10.1634/theoncologist.2013-0369 |url=}}</ref> | *The following table illustrates the differences between Sporadic and MEN-1-associated ZES: <ref name="pmid24319020">{{cite journal |vauthors=Epelboym I, Mazeh H |title=Zollinger-Ellison syndrome: classical considerations and current controversies |journal=Oncologist |volume=19 |issue=1 |pages=44–50 |year=2014 |pmid=24319020 |pmc=3903066 |doi=10.1634/theoncologist.2013-0369 |url=}}</ref> | ||
{| style="border: 0px; font-size: | {| style="border: 0px; font-size: 110%; margin: 3px;" align=center | ||
| colspan="3" style="background: #4479BA; text-align: center;" | {{fontcolor|#FFF|'''Sporadic and MEN-1-associated ZES'''}} | | colspan="3" style="background: #4479BA; text-align: center;" | {{fontcolor|#FFF|'''Sporadic and MEN-1-associated ZES'''}} | ||
|+ | |+ | ||
Revision as of 19:00, 3 August 2017
|
Zollinger-Ellison syndrome Microchapters |
|
Differentiating Zollinger-Ellison syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Zollinger-Ellison syndrome classification On the Web |
|
American Roentgen Ray Society Images of Zollinger-Ellison syndrome classification |
|
Risk calculators and risk factors for Zollinger-Ellison syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
- The World Health Organization classifies neuroendocrine tumors (NETs) into two broad categories, well differentiated and poorly differentiated, and most gastrinomas are considered well-differentiated neuroendocrine tumors (NETs) on the basis of histopathological analysis.
Classiffication
- Gastrinomas are derived from the enteroendocrine cells that arise from the embryologic endoderm, and form tumors mainly in the pancreas, but also in the proximal small intestine. Because of their origin, these are generally classified under the larger umbrella term of neuroendocrine tumors (NETs). [1]
- The World Health Organization classifies neuroendocrine tumors (NETs) into two broad categories, well differentiated and poorly differentiated, and most gastrinomas are considered well-differentiated neuroendocrine tumors (NETs) on the basis of histopathological analysis. It has been observed that most gastrinomas arise in the duodenum, with tumors located in the pancreas carrying greater malignant potential. [2]
- The following table illustrates the differences between Sporadic and MEN-1-associated ZES: [3]
| Sporadic and MEN-1-associated ZES | ||
| Factors | Sopradic ZES | MEN-1 ZES |
|---|---|---|
|
|
|
References
- ↑ Norton JA (1994). "Neuroendocrine tumors of the pancreas and duodenum". Curr Probl Surg. 31 (2): 77–156. PMID 7904550.
- ↑ O'Toole D, Delle Fave G, Jensen RT (2012). "Gastric and duodenal neuroendocrine tumours". Best Pract Res Clin Gastroenterol. 26 (6): 719–35. doi:10.1016/j.bpg.2013.01.002. PMID 23582915.
- ↑ Epelboym I, Mazeh H (2014). "Zollinger-Ellison syndrome: classical considerations and current controversies". Oncologist. 19 (1): 44–50. doi:10.1634/theoncologist.2013-0369. PMC 3903066. PMID 24319020.